The FLOW-AF multicenter, randomized controlled trial shows Ablacon's Electrographic Flow® (EGF®) Mapping software (Ablamap®) results in improved ablation outcomes in persistent atrial fibrillation
/PRNewswire/ -- Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation...
Source: prnewswire.com